Literature DB >> 23868869

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.

Christopher J Nirschl1, Charles G Drake.   

Abstract

The expression of immune checkpoint molecules on T cells represents an important mechanism that the immune system uses to regulate responses to self-proteins. Checkpoint molecules include cytotoxic T lymphocyte antigen-4, programmed death-1, lymphocyte activation gene-3, T-cell immunoglobulin and mucin protein-3, and several others. Previous studies have identified individual roles for each of these molecules, but more recent data show that coexpression of checkpoint molecules occurs frequently on cancer-specific T cells as well as on pathogen-specific T cells in chronic infections. As the signaling pathways associated with each checkpoint molecule have not been fully elucidated, blocking multiple checkpoints with specific monoclonal antibodies results in improved outcomes in several chronic viral infections as well as in a wide array of preclinical models of cancer. Recent clinical data suggest similar effects in patients with metastatic melanoma. These findings support the concept that individual immune checkpoint molecules may function through nonoverlapping molecular mechanisms. Here, we review current data regarding immune checkpoint molecule signaling and coexpression, both in cancer and infectious disease, as well as the results of preclinical and clinical manipulations of checkpoint proteins. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23868869      PMCID: PMC4005613          DOI: 10.1158/1078-0432.CCR-12-1972

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

Authors:  E Chuang; T S Fisher; R W Morgan; M D Robbins; J M Duerr; M G Vander Heiden; J P Gardner; J E Hambor; M J Neveu; C B Thompson
Journal:  Immunity       Date:  2000-09       Impact factor: 31.745

Review 2.  Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Authors:  Lieping Chen
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

3.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

Authors:  Kelly-Ann Sheppard; Lori J Fitz; Julie M Lee; Christina Benander; Judith A George; Joe Wooters; Yongchang Qiu; Jason M Jussif; Laura L Carter; Clive R Wood; Divya Chaudhary
Journal:  FEBS Lett       Date:  2004-09-10       Impact factor: 4.124

4.  Role of LAG-3 in regulatory T cells.

Authors:  Ching-Tai Huang; Creg J Workman; Dallas Flies; Xiaoyu Pan; Aimee L Marson; Gang Zhou; Edward L Hipkiss; Sowmya Ravi; Jeanne Kowalski; Hyam I Levitsky; Jonathan D Powell; Drew M Pardoll; Charles G Drake; Dario A A Vignali
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

5.  Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Authors:  Sara M Mangsbo; Linda C Sandin; Kerstin Anger; Alan J Korman; Angelica Loskog; Thomas H Tötterman
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

6.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

7.  The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells.

Authors:  Creg J Workman; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

8.  Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

Authors:  Alberto Sánchez-Fueyo; Jane Tian; Dominic Picarella; Christoph Domenig; Xin Xiao Zheng; Catherine A Sabatos; Natasha Manlongat; Orissa Bender; Thomas Kamradt; Vijay K Kuchroo; José-Carlos Gutiérrez-Ramos; Anthony J Coyle; Terry B Strom
Journal:  Nat Immunol       Date:  2003-10-12       Impact factor: 25.606

9.  SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.

Authors:  Jens M Chemnitz; Richard V Parry; Kim E Nichols; Carl H June; James L Riley
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

View more
  109 in total

1.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

Review 2.  Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance.

Authors:  Christopher J Nirschl; Niroshana Anandasabapathy
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.

Authors:  Yu Jin Lim; Jaemoon Koh; Kyubo Kim; Eui Kyu Chie; Sehui Kim; Kyoung Bun Lee; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 4.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

5.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

6.  NLRX1 Regulates Effector and Metabolic Functions of CD4+ T Cells.

Authors:  Andrew Leber; Raquel Hontecillas; Nuria Tubau-Juni; Victoria Zoccoli-Rodriguez; Matthew Hulver; Ryan McMillan; Kristin Eden; Irving C Allen; Josep Bassaganya-Riera
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

Review 7.  The emerging role of immunotherapy in colorectal cancer.

Authors:  David Lynch; Adrian Murphy
Journal:  Ann Transl Med       Date:  2016-08

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 9.  Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.

Authors:  Alessia Mennitto; Paolo Grassi; Raffaele Ratta; Elena Verzoni; Michele Prisciandaro; Giuseppe Procopio
Journal:  Ther Adv Urol       Date:  2016-07-07

10.  Potentiating cancer vaccine efficacy in liver cancer.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.